Patents by Inventor Richard A. Metz
Richard A. Metz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11160224Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.Type: GrantFiled: July 30, 2018Date of Patent: November 2, 2021Assignee: CIBUS US LLCInventors: Peter R. Beetham, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
-
Publication number: 20180355327Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.Type: ApplicationFiled: July 30, 2018Publication date: December 13, 2018Applicant: CIBUS US LLCInventors: PETER R. BEETHAM, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
-
Patent number: 10035991Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.Type: GrantFiled: November 16, 2007Date of Patent: July 31, 2018Assignee: CIBUS US LLCInventors: Peter R. Beetham, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
-
Patent number: 8436151Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.Type: GrantFiled: November 4, 2011Date of Patent: May 7, 2013Assignee: Lankenau Institute for Medical ResearchInventors: George C. Prendergast, Richard Metz
-
Publication number: 20120090044Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.Type: ApplicationFiled: November 4, 2011Publication date: April 12, 2012Inventors: George C. Prendergast, Richard Metz
-
Patent number: 8058416Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.Type: GrantFiled: November 18, 2008Date of Patent: November 15, 2011Assignee: Lankenau Institute for Medical ResearchInventors: George C. Prendergast, Richard Metz
-
Publication number: 20090158451Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.Type: ApplicationFiled: November 18, 2008Publication date: June 18, 2009Inventors: George C. Prendergast, Richard Metz
-
Publication number: 20080256668Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphoniorethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phophonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.Type: ApplicationFiled: November 16, 2007Publication date: October 16, 2008Inventors: PETER R. BEETHAM, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
-
Patent number: 7060500Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in animal, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammalian cells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2?-O-methyl ribonucleotides.Type: GrantFiled: November 12, 2002Date of Patent: June 13, 2006Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
-
Patent number: 6929917Abstract: The invention concerns a new method of detecting a rare product of a directed genetic alteration of a cultured cell. The method is applicable to any method of making the alteration provided that a pair of closely linked alterations can be made. The method consists of sequentially using allele specific polymerase chain reaction (PCR) to preferentially amplify sequences containing one of the two linked alterations coupled with a second method that detects the second change in the PCR product. The second method can be restriction digestion, traditional sequencing or pyro-sequencing. Experiments indicate that alterations as rare as one correctly altered copy in 10,000 cells can be detected.Type: GrantFiled: November 18, 2002Date of Patent: August 16, 2005Assignee: PreGentisInventors: Richard Metz, Mike DiCola, R. Michael Blaese
-
Publication number: 20050177899Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.Type: ApplicationFiled: February 4, 2005Publication date: August 11, 2005Inventors: Peter Beetham, Patricia Avissar, Keith Walker, Richard Metz
-
Patent number: 6870075Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide.Type: GrantFiled: October 10, 2000Date of Patent: March 22, 2005Assignee: Valigen (US), Inc.Inventors: Peter R. Beetham, Patricia L. Avissar, Keith A. Walker, Richard A. Metz
-
Publication number: 20040096832Abstract: The invention concerns a new method of detecting a rare product of a directed genetic alteration of a cultured cell. The method is applicable to any method of making the alteration provided that a pair of closely linked alterations can be made. The method consists of sequentially using allele specific polymerase chain reaction (PCR) to preferentially amplify sequences containing one of the two linked alterations coupled with a second method that detects the second change in the PCR product. The second method can be restriction digestion, traditional sequencing or pyro-sequencing. Experiments indicate that alterations as rare as one correctly altered copy in 10,000 cells can be detected.Type: ApplicationFiled: November 18, 2002Publication date: May 20, 2004Inventors: Richard Metz, Mike DiCola, R. Michael Blaese
-
Publication number: 20040023392Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in animal, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammalian cells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2′-O-methyl ribonucleotides.Type: ApplicationFiled: November 12, 2002Publication date: February 5, 2004Applicant: ValiGen (US), Inc.Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
-
Publication number: 20030229910Abstract: A method for generating cattle resistant to Bovine Spongioform Encephalopathy through targeted alterations in the PrP gene is disclosed. The PrP gene of a cultured cells is altered to prevent its translation or to encode a dominant disease-resistant form of the protein, and the nucleus of the altered cell is used to clone a founder animal. In one embodiment, a single-stranded DNA fragment containing the alteration is used in single-stranded short fragment homologous replacement to alter the PrP gene.Type: ApplicationFiled: April 17, 2003Publication date: December 11, 2003Inventors: Richard Metz, R. Michael Blaese
-
Patent number: 6586184Abstract: The invention is based on the discovery that recombinagenic oligonucleobases are active in prokaryotic cells that contain a strand transfer activity (RecA) and mismatch repair activity (MutS). Using this system a type of Duplex Mutational Vector termed a Heteroduplex Mutational Vector, was shown to be more active in prokaryotic cells than the types of mutational vectors heretofore tested. Further improvements in activity were obtained by replacing the tetrathymidine linker by a nuclease resistant oligonucleotide, such as tetra-2′-O-methyl-uridine, to link the two strands of the recombinagenic oligonucleobase and removing the DNA-containing intervening segment. The claims concern Duplex Mutational Vectors that contain the above improvements. In an alternative embodiment the claims concern the use of Duplex Mutational Vectors in prokaryotic cells.Type: GrantFiled: April 3, 2001Date of Patent: July 1, 2003Assignee: ValiGen (U.S.), Inc.Inventors: Ramesh Kumar, Richard A. Metz
-
Publication number: 20020184043Abstract: A method for management of business metrics using a system including a server and at least one user accessible device communicative with the server, the server having a database and a web interface, the method providing user with a web interface configurable to a template accommodating business metrics data by the user. An apparatus comprising a computer, a server configured with a database enabled for storing and retrieving a web interface, the server additionally configured to upload and store business metrics data in a database, and a network communicative with the server and a user device connected to the network.Type: ApplicationFiled: June 4, 2001Publication date: December 5, 2002Inventors: Egidio Lavorgna, Ramesh Thuravil, Richard Metz
-
Patent number: 6479292Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in animal, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammalian cells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2′-O-methyl ribonucleotides.Type: GrantFiled: August 25, 2000Date of Patent: November 12, 2002Assignee: ValiGen (US), Inc.Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
-
Publication number: 20020151072Abstract: The invention is based on the discovery that recombinagenic oligonucleobases are active in prokaryotic cells that contain a strand transfer activity (RecA) and mismatch repair activity (MutS). Using this system a type of Duplex Mutational Vector termed a Heteroduplex Mutational Vector, was shown to be more active in prokaryotic cells than the types of mutational vectors heretofore tested. Further improvements in activity were obtained by replacing the tetrathymidine linker by a nuclease resistant oligonucleotide, such as tetra-2′-O-methyl-uridine, to link the two strands of the recombinagenic oligonucleobase and removing the DNA-containing intervening segment. The claims concern Duplex Mutational Vectors that contain the above improvements. In an alternative embodiment the claims concern the use of Duplex Mutational Vectors in prokaryotic cells.Type: ApplicationFiled: April 3, 2001Publication date: October 17, 2002Applicant: ValiGen (U.S), Inc.Inventors: Ramesh Kumar, Richard A. Metz
-
Patent number: RE49708Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.Type: GrantFiled: January 8, 2021Date of Patent: October 24, 2023Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCHInventors: George C. Prendergast, Richard Metz